Diabetic cardiomyopathy is a critical complication requiring early detection and management with ACE inhibitors, beta-blockers, and metabolic control.
Supports monitoring in diabetic cardiomyopathy; leaves open prospective validation of ACE inhibitors and beta-blockers.
Diabetes is one of the principal problems concerning the health of contemporary society. It causes numerous dangerous complications among which cardiological complications take up the fi rst place because they can lead to quick deaths of patients. Cardiomyopathy is an essential and at the same time insidiously developing complication of diabetes. It is the result of the combined action of unfavourable factors such as: endotheliopathy, autonomic system dysfunction, disturbances of carbohydrate metabolism and consequently ischaemic heart disease as well as arterial hypertension. The problem of diabetic cardiomyopathy demands a regular monitoring of cardiovascular system and a quick introduction of pharmacological treatment at its fi rst symptoms. There are opinions more and more frequently presented that suggest prophylactic administration of cardiological drugs in the group of asymptomatic patients. According to the European Society of Cardiology, two groups of medications are recommended: angiotensin converting enzyme inhibitors and beta-adrenalytics. The treatment of cardiomyopathy in diabetic patients should also include normalization of the body mass and an accurate metabolic compensation.
No takes yet. Share an insight, caveat, or question.
Ciurysek et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: